First Hep C protease head-to-head trial pits Medivir's TMC435 against J&J's telaprevir
This article was originally published in Scrip
Executive Summary
In what is the first of its kind – and might well be the last - the protease inhibitor drug TMC435 developed by J&J unit Janssen Pharmaceuticals in collaboration with Swedish anti-infectives company Medivir is to begin a first head-to-head of trial of its against Vertex/Johnson & Johnson's approved hepatitis C protease inhibitor, Incivek (telaprevir).